InsidersTradesSigma
Follow the Gilead Sciences INC share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Gilead Sciences INC has recorded 43 public disclosures. Market capitalisation: €162.3bn. The latest transaction was filed on 11 February 2022 (Cession). Among the most active insiders: MARTIN JOHN C. All data is accessible without an account.
43
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€2m
11 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Gilead Sciences INC Buy (bullish), based on 27 analysts. Average price target: US$158.30.
27Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,793 of 29,062 companies
59.6
score / 100
Value57
Quality62
FCF yld5.6%
Earn yld5.0%
EV/EBITDA14.3x
ROE-21%
Gross mgn79%
Net mgn29%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 February 2022
Declarations43 total
1,691 shares@ US$63.890.0001% mcap5.0% of flowCommon StockSEC:0001127602-22-004516:0
1,864 shares0Common StockSEC:0001127602-22-003845:0
1,817 shares0Common StockSEC:0001127602-22-003847:0
2,727 shares0Common StockSEC:0001127602-22-003846:0
14,061 shares@ US$68.53580.0006% mcap45.0% of flowCommon StockSEC:0001127602-22-003048:0
1,714 shares0Common StockSEC:0001127602-22-002464:0
19,020 shares0Common StockSEC:0001127602-22-002463:0
20,298 shares0Common StockSEC:0001127602-22-002465:0
64,008 shares0Common StockSEC:0001127602-22-002466:0
15,262 shares0Common StockSEC:0001127602-22-002462:0
18,630 shares0Common StockSEC:0001127602-22-002467:0
1,041 sharesCommon StockSEC:0001127602-21-030577:0
1,913 sharesCommon StockSEC:0001127602-21-029039:0
5,100 sharesCommon StockSEC:0001127602-21-029042:0
1,368 sharesCommon StockSEC:0001127602-21-027629:0
32 shares@ US$55.080.2% of flowCommon StockSEC:0001127602-21-024266:0
1 shares@ US$55.08100.0% of flowCommon StockSEC:0001127602-21-024261:0
1 shares@ US$55.08100.0% of flowCommon StockSEC:0001127602-21-024264:0
9,781 shares@ US$68.75100.0% of flowCommon StockSEC:0001127602-21-023999:0
2,480 sharesCommon StockSEC:0001127602-21-023570:0
7,505 sharesCommon StockSEC:0001127602-21-022506:0
1,838 sharesCommon StockSEC:0001127602-21-020005:0
3,646 sharesCommon StockSEC:0001127602-21-019794:0
1,936 sharesCommon StockSEC:0001127602-21-015950:0
1,936 sharesCommon StockSEC:0001127602-21-015956:0
25 of 43 declarations
关于 Gilead Sciences INC
GILEAD SCIENCES INC（股票代码 GILD）是一家在美国纳斯达克市场交易的美国上市生物制药公司，总部位于加利福尼亚州福斯特城。Gilead 成立于 1987 年，已发展成为治疗严重和危及生命疾病的全球领导者，战略重点放在三个核心治疗领域：病毒学、肿瘤学和炎症。对于国际投资者而言，该公司作为一家大型医疗保健公司脱颖而出，它结合了成熟的商业特许经营权、强大的科学能力和长期的创新管线。 Gilead 的历史优势在于病毒学，尤其是 HIV 和病毒性肝炎。其商业产品组合包括主要的 HIV 品牌，如 Biktarvy 和 Descovy，以及肝病疗法和用于 COVID-19 相关治疗的 Veklury，尽管后者对整体增长的重要性已有所下降。在肿瘤学领域，Gilead 通过其细胞疗法业务 Kite 进行了扩张，而炎症已成为公司研发战略中日益重要的支柱。这种更广泛的治疗组合具有战略意义，因为它减少了对单一特许经营权的长期依赖，并为增长创造了额外的途径。 从竞争角度来看，Gilead 仍然是 HIV 护理领域最重要的参与者之一，这得益于强大的品牌认知度、深厚的临床专业知识和广泛的全球足迹。该公司在超过 35 个国家开展业务，并在全球销售超过 25 种药物。它还在病毒学、肿瘤学和炎症领域拥有庞大的临床管线，这对于在竞争激烈的制药领域保持其相关性至关重要。Gilead 的规模、制造能力和合作伙伴关系使其能够与全球其他大型制药和生物技术公司竞争。 最近的发展值得关注。2026 年，Gilead 报告 2025 财年收入约为 29.4 billion 美元，增长主要由 HIV 和肝病产品推动。该公司强调了 lenacapavir 方面的进展，并宣布了旨在扩大低收入市场可及性的以可及性为导向的合作伙伴关系。Gilead 还继续投资于美国的研发和制造，包括在其福斯特城总部的新基础设施，这突显了其对国内创新和供应链能力的长期承诺。总的来说，Gilead 是一家高质量的医疗保健公司，拥有成熟的创收基础和有望支持下一阶段增长的管线。
